Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Lyell Immunopharma Inc (Lyell) is a clinical-stage cell therapy company. It develops next-generation CAR T-cell therapies for treating hematologic malignancies and solid tumors. The company's pipeline products include Ronde-Cel or LYL314 for the treatment of B-cell lymphoma; and LYL273 is a novel autologous guanylyl cyclase-C (GCC) which targets metastatic colorectal cancer (mCRC). It utilised CAR T-Cell Therapy is a type of personalized immunotherapy that involves taking cells from the patient, improving their functionality and cancer-fighting ability, and then transferring them back to the patient via a single intravenous infusion.Lyell is headquartered in San Francisco, California, the US.
Headquarters
United States of America
Address
201 Haskins Way, Suite 301, San Francisco, California, 94080
Website
lyell.com
No of Employees
161
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
LYEL (NASD)
Revenue (2024)
$36,000
-41%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
20%
(2024 vs 2023)
Market Cap*
$302.6M
Net Profit Margin (2024)
XYZ
-35.6%
(2024 vs 2023)
* As of and is in US$
Lyell Immunopharma Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Lyell |
| Ronde-Cel or LYL314: B-cell lymphoma | |
| LYL273: Metastatic Colorectal Cancer (mCRC) |
Competitor Comparison
| Key Parameters | Lyell Immunopharma Inc | Sangamo Therapeutics Inc | Pharmedic Pharmaceutical Medicinal JSC | Allogene Therapeutics Inc | Clondalkin Pharma & Healthcare (Northampton) Ltd. |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Vietnam | United States of America | United Kingdom |
| City | San Francisco | Richmond | Ho Chi Minh City | San Francisco | Northampton |
| State/Province | California | California | - | California | England |
| No. of Employees | 161 | 142 | 516 | 150 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Rick Klausner, M.D. | Chairman | Executive Board | 2018 | 73 |
| Lynn Seely, M.D. | Chief Executive Officer; Director; President | Executive Board | 2021 | 67 |
| Smital Shah | Chief Financial Officer; Chief Business Officer | Senior Management | 2026 | 49 |
| Stephen Hill | Chief Operating Officer | Senior Management | 2021 | 55 |
| David Shook, M.D. | Chief Medical Officer | Senior Management | 2025 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer